Navigation Links
Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
Date:2/8/2013

d party contractors for certain goods and services, and any inability of these third party manufacturers to manufacture products, or any failure of these third party contractors to provide these goods and services, in each case in accordance with its respective contractual obligations, could adversely affect Shire's ability to manage its manufacturing processes or to operate its business;
  • the development, approval and manufacturing of Shire's products is subject to extensive oversight by various regulatory agencies and regulatory approvals or interventions associated with changes to manufacturing sites, ingredients or manufacturing processes could lead to significant delays, increase in operating costs, lost product sales, an interruption of research activities or the delay of new product launches;
  • the actions of certain customers could affect Shire 's ability to sell or market products profitably and fluctuations in buying or distribution patterns by such customers could adversely impact Shire's revenues, financial conditions or results of operations;
  • investigations or enforcement action by regulatory authorities or law enforcement agencies relating to Shire's activities in the highly regulated markets in which it operates may result in the distraction of senior management, significant legal costs and the payment of substantial compensation or fines;
  • adverse outcomes in legal matters and other disputes, including Shire's ability to obtain, maintain, enforce and defend patents and other intellectual property rights required for its business, could have a material adverse effect on Shire's revenues, financial condition or results of operations;
  • and other risks and uncertainties detailed from time to time in Shire's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K.

    i. Fine J-D, Johnson  LB, Suchindran C, Gedde-DahI T (1999e) The Epidemiology of I
    '/>"/>

    SOURCE Shire plc
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
    2. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
    3. Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012
    4. Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
    5. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
    6. Shire Changes its NASDAQ Ticker Symbol to SHPG
    7. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
    8. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
    9. Shire Reaches Agreement in Principle With U.S. Government
    10. Palm Beach Residents to Learn How the Future of Regenerative Medicine Will Combat Aging
    11. ODT Forum Presents Regenerative Technologies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/23/2015)... , April 23, 2015 /CNW/ - A new and ... award from North America,s ... Comparison won Silver in the "Sustainability, service" category ... The Brandcheck "Competitor Comparison" is a service that ... American and Global peers. This benchmarking process shows ...
    (Date:4/23/2015)... 23, 2015 WuXi PharmaTech (Cayman) Inc. (NYSE: ... technology platform company serving the pharmaceutical, biotechnology and medical ... and the United States , ... the first quarter of 2015 after the New York ... will be Thursday morning, May 14, 2015 Shanghai time). ...
    (Date:4/23/2015)... , April 23, 2015 ... Equipment   Report Details   We ... a value of $101.3 billion in 2015 and will grow ... growth in the healthcare sectors around the world and increasing ... key growth factors in the global healthcare packaging ...
    (Date:4/23/2015)... YORK , April 23, 2015  Propanc ... stage healthcare company, focuses on the development of ... cancer. The company lead product includes PRP, a ... trypsinogen and chymotrypsinogen, as well as the enzyme ... is also developing a combination of anti-cancer agents ...
    Breaking Biology Technology:WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 3Healthcare Packaging Market Forecast 2015-2025 2Healthcare Packaging Market Forecast 2015-2025 3Healthcare Packaging Market Forecast 2015-2025 4Healthcare Packaging Market Forecast 2015-2025 5Healthcare Packaging Market Forecast 2015-2025 6Healthcare Packaging Market Forecast 2015-2025 7Healthcare Packaging Market Forecast 2015-2025 8Healthcare Packaging Market Forecast 2015-2025 9Healthcare Packaging Market Forecast 2015-2025 10Early Stage BioTech offers Plenty of Risk; Propanc Health Group Analyst Brief Issued by BrokerBank Securities, Inc. 2
    ... Oct. ... , ... 30, 2009 -- The Boston biotechnology industry will get an early look at biotech,s future ... 2009 at Harvard Medical School. , , ,At the one-day event, recently funded companies will ...
    ... In its newly published Lockton Market Update ... that the markets are in a relative state of calm ... The online update includes snapshots of more than two dozen ... officers and other executives. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090415/CG99351LOGO ...
    ... PRINCETON, N.J., Sept. 30 DOR BioPharma, Inc. (OTC Bulletin ... has completed a corporate name change from DOR BioPharma, Inc. ... of the name change, the Company,s shares of common stock ... as of today. , "We are pleased to ...
    Cached Biology Technology:Boston Biotech R&D Conference to Showcase Next-Generation Newsmakers and Massachusetts as Leader in Biotech Discovery 2Boston Biotech R&D Conference to Showcase Next-Generation Newsmakers and Massachusetts as Leader in Biotech Discovery 3Commercial Insurance Buyers Benefit From Ample Capacity 2Commercial Insurance Buyers Benefit From Ample Capacity 3DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol 'SNGX' 2DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol 'SNGX' 3DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol 'SNGX' 4
    (Date:4/17/2015)... 17, 2015 Increasing ... technological advancement to drive biometric systems market in ...   According to a recently released ... &  Opportunities, 2020 ", biometric systems market in ... growth at CAGR of over 22% through 2020. ...
    (Date:4/10/2015)... , April 10, 2015 ... addition of the "Security Competitive Profiles - NEC" ... http://photos.prnewswire.com/prnh/20130307/600769) , NEC will continue to supply ... to the market, with a company focus on the ... anticipated. Winning opportunities in the ...
    (Date:4/2/2015)... -- At its 2015 ACMG Annual Clinical Genetics Meeting ... American College of Medical Genetics and Genomics (ACMG) announced ... Members of the ACMG Board of Directors serve as ... its policies and programs. ACMG is the national organization ... eventful time in medical genetics and genomics.  We are ...
    Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NEC Security Competitive Profile 2015 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8
    ... wastewater fuel cell, researchers have coaxed common bacteria to ... Logan and colleagues at Penn State University had already ... using starter material that could theoretically be sourced from ... microbes to generate hydrogen. By tweaking their design, ...
    ... 2007) A major study that will provide a new ... conducted by the La Jolla Institute for Allergy & ... The five-year study, funded by the National Institute of ... Institutes of Health, could lead to revolutionary new approaches ...
    ... Nov. 12, 2007 Visually unsettling and intellectually provocative, John ... Chervinsky, a photographer with a strong background in physics, ... Experiment in Perspective at the University of Houston at 7 ... Hoffman Hall. The event is free and open to ...
    Cached Biology News:Microbes churn out hydrogen at record rate 2NIH selects LIAI for major study on allergy molecular causes and possible treatments 2NIH selects LIAI for major study on allergy molecular causes and possible treatments 3NIH selects LIAI for major study on allergy molecular causes and possible treatments 4Art meets science: Engineer discusses his photographs in free UH lecture 2